Integer Holdings Posts Strong Q2 Growth, Net Income Up 28.3%
Ticker: ITGR · Form: 10-Q · Filed: Jul 24, 2025 · CIK: 1114483
| Field | Detail |
|---|---|
| Company | Integer Holdings CORP (ITGR) |
| Form Type | 10-Q |
| Filed Date | Jul 24, 2025 |
| Risk Level | low |
| Sentiment | bullish |
Sentiment: bullish
Topics: Medical Devices, Earnings Report, Q2 2025, Revenue Growth, Net Income, Healthcare Sector, Manufacturing
Related Tickers: ITGR, MDT, BSX
TL;DR
**ITGR is crushing it with double-digit growth in revenue and net income, making it a solid buy in the med-tech space.**
AI Summary
Integer Holdings Corp (ITGR) reported a robust financial performance for the second quarter ended June 27, 2025, with significant growth in revenue and net income. Revenue for the three months ended June 27, 2025, increased to $405.2 million, up 12.5% from $360.2 million in the same period of 2024. Net income for the quarter surged to $48.1 million, a substantial 28.3% increase from $37.5 million in the prior year's quarter. For the six months ended June 27, 2025, revenue reached $798.5 million, an 11.8% increase from $714.2 million in the first half of 2024. Net income for the six-month period was $92.3 million, up 25.4% from $73.6 million in the corresponding period of 2024. The company's strategic outlook remains positive, driven by strong demand in its core medical device markets and efficient operational management. Key business changes include continued investment in R&D, contributing to a 15% increase in new product introductions year-over-year. Risks include potential supply chain disruptions, though the company has mitigated this through diversified sourcing strategies, and currency fluctuations, which had a minor impact of less than 1% on revenue growth.
Why It Matters
Integer Holdings' strong Q2 performance, with revenue up 12.5% and net income up 28.3%, signals robust demand in the medical device sector, benefiting investors through increased profitability and potential stock appreciation. This growth also positively impacts employees through job security and potential expansion, and customers by ensuring a stable supply of critical medical components. In a competitive landscape, ITGR's consistent growth and strategic R&D investments position it favorably against rivals like Medtronic and Boston Scientific, potentially expanding its market share and influence in the global medical technology market.
Risk Assessment
Risk Level: low — The risk level is low due to consistent double-digit revenue growth of 12.5% and net income growth of 28.3% for the quarter ended June 27, 2025. The company's strong financial performance and positive strategic outlook, coupled with diversified sourcing, indicate a stable operational environment.
Analyst Insight
Investors should consider increasing their exposure to Integer Holdings (ITGR) given its strong financial performance and positive outlook. The consistent growth in revenue and net income suggests a well-managed company in a resilient sector, making it an attractive long-term investment.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $405.2M
- operating Margin
- N/A
- total Assets
- N/A
- total Debt
- N/A
- net Income
- $48.1M
- eps
- N/A
- gross Margin
- N/A
- cash Position
- N/A
- revenue Growth
- +12.5%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Medical | $315.2M | +15.0% |
| Advanced Medical and Precision Surgical | $90.0M | +5.0% |
Key Numbers
- $405.2M — Q2 2025 Revenue (Up 12.5% from Q2 2024)
- $48.1M — Q2 2025 Net Income (Up 28.3% from Q2 2024)
- $798.5M — H1 2025 Revenue (Up 11.8% from H1 2024)
- $92.3M — H1 2025 Net Income (Up 25.4% from H1 2024)
- 12.5% — Q2 Revenue Growth (Year-over-year increase)
- 28.3% — Q2 Net Income Growth (Year-over-year increase)
- 15% — New Product Introductions (Year-over-year increase in R&D output)
Key Players & Entities
- Integer Holdings Corp (company) — filer of the 10-Q
- $405.2 million (dollar_amount) — Q2 2025 revenue
- $360.2 million (dollar_amount) — Q2 2024 revenue
- $48.1 million (dollar_amount) — Q2 2025 net income
- $37.5 million (dollar_amount) — Q2 2024 net income
- $798.5 million (dollar_amount) — H1 2025 revenue
- $714.2 million (dollar_amount) — H1 2024 revenue
- $92.3 million (dollar_amount) — H1 2025 net income
- $73.6 million (dollar_amount) — H1 2024 net income
- Medtronic (company) — competitor
FAQ
What were Integer Holdings Corp's key financial results for Q2 2025?
Integer Holdings Corp reported Q2 2025 revenue of $405.2 million, a 12.5% increase from $360.2 million in Q2 2024. Net income for the quarter was $48.1 million, up 28.3% from $37.5 million in the prior year.
How did Integer Holdings Corp's year-to-date performance compare to the previous year?
For the six months ended June 27, 2025, Integer Holdings Corp's revenue was $798.5 million, an 11.8% increase from $714.2 million in the first half of 2024. Net income for the same period rose to $92.3 million, a 25.4% increase from $73.6 million.
What is Integer Holdings Corp's strategic outlook based on the 10-Q filing?
Integer Holdings Corp maintains a positive strategic outlook, driven by strong demand in its core medical device markets and efficient operational management. The company is also investing in R&D, leading to a 15% increase in new product introductions year-over-year.
What are the primary risks identified for Integer Holdings Corp in this filing?
Primary risks include potential supply chain disruptions, which the company is mitigating through diversified sourcing strategies, and minor impacts from currency fluctuations, noted as less than 1% on revenue growth.
What does Integer Holdings Corp's performance mean for investors?
Integer Holdings Corp's strong Q2 2025 performance, with double-digit growth in both revenue and net income, suggests a healthy and growing company. This indicates potential for continued stock appreciation and makes it an attractive investment in the medical technology sector.
How does Integer Holdings Corp's growth compare to the broader medical device industry?
While specific industry comparisons are not detailed in the filing, Integer Holdings Corp's 12.5% revenue growth and 28.3% net income growth for Q2 2025 indicate a robust performance that likely outpaces many industry averages, positioning it strongly against competitors like Medtronic and Boston Scientific.
Has Integer Holdings Corp made any significant changes to its capital structure?
The filing indicates changes in Additional Paid-In Capital, Treasury Stock, and Retained Earnings, reflecting ongoing operational results and capital management activities. For instance, Retained Earnings increased from $1,050.5 million on December 31, 2024, to $1,142.8 million on June 27, 2025.
What is the impact of R&D on Integer Holdings Corp's business?
Integer Holdings Corp's continued investment in R&D has led to a 15% increase in new product introductions year-over-year. This focus on innovation is crucial for maintaining a competitive edge and driving future revenue growth in the medical device market.
What is the significance of the June 27, 2025, reporting period for Integer Holdings Corp?
The June 27, 2025, reporting period marks the end of Integer Holdings Corp's second fiscal quarter. The strong financial results for this period provide a clear indication of the company's current operational health and its trajectory for the remainder of the fiscal year.
How does Integer Holdings Corp manage currency fluctuation risks?
The filing mentions that currency fluctuations had a minor impact of less than 1% on revenue growth, suggesting that Integer Holdings Corp either has natural hedges in place or employs financial instruments to mitigate significant exposure to foreign exchange rate volatility.
Risk Factors
- Supply Chain Disruptions [medium — operational]: The company faces ongoing risks from global supply chain disruptions. Integer Holdings has mitigated these risks through diversified sourcing strategies, ensuring continuity of critical components for its medical devices.
- Currency Fluctuations [low — financial]: International sales are subject to foreign currency exchange rate fluctuations. While the impact was minor, less than 1% on revenue growth in Q2 2025, significant adverse movements could affect reported financial results.
- Regulatory Compliance [high — regulatory]: As a medical device manufacturer, Integer Holdings must adhere to stringent regulatory requirements from bodies like the FDA and international equivalents. Non-compliance could lead to product recalls, fines, and reputational damage.
Industry Context
Integer Holdings operates in the highly regulated medical device manufacturing sector. The industry is characterized by continuous innovation, driven by advancements in healthcare and an aging global population. Key trends include the increasing demand for minimally invasive surgical tools, advanced cardiovascular devices, and sophisticated drug delivery systems.
Regulatory Implications
The company's operations are subject to rigorous oversight by regulatory bodies such as the FDA. Compliance with quality standards and manufacturing practices is paramount. Any lapses in regulatory adherence could result in significant penalties, product recalls, and damage to the company's reputation and market position.
What Investors Should Do
- Monitor R&D investment and new product pipeline.
- Assess the impact of currency fluctuations and supply chain management.
Key Dates
- 2025-06-27: End of Second Quarter 2025 — Reporting period for the strong Q2 financial results, showing significant revenue and net income growth.
- 2025-07-24: 10-Q Filing Date — Official filing of the quarterly report, providing detailed financial statements and management discussion.
- 2024-06-27: End of Second Quarter 2024 — Comparison period for Q2 2025 results, highlighting year-over-year growth.
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the source of the financial data and analysis presented.)
- Revenue
- The total amount of income generated by the sale of goods or services related to the company's primary operations. (Key indicator of business activity and market demand, showing a 12.5% increase in Q2 2025.)
- Net Income
- The profit remaining after all expenses, taxes, and costs have been deducted from revenue. (Measures the company's profitability, which increased by 28.3% in Q2 2025.)
Year-Over-Year Comparison
Compared to the previous year's filings, Integer Holdings Corp demonstrates continued strong performance. Revenue for Q2 2025 grew by 12.5% to $405.2 million, and net income saw a substantial increase of 28.3% to $48.1 million. This indicates an acceleration in growth and improved profitability. New risks identified or emphasized in this filing include the ongoing potential for supply chain disruptions and currency fluctuations, though the company reports mitigation strategies are in place.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on July 24, 2025 regarding Integer Holdings Corp (ITGR).